Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          HHS Search block
    Search
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    Home
                              About
                              Agencies
                              DAB
                              Decisions
                              ALJ Decisions
                              2023 ALJ Decisions
                              In re LCD Complaint: Rituximab (L33394), DAB CR6220 (2023)
 Navigate to:
  Departmental Appeals Board (DAB)
    
                                                  
                                                    
            
      
      
      
      About DAB
                                            
            
            Organizational Overview
    
                                                  
                              
            
      
      
      
      Who are the Judges?
    
                                                  
                              
            
      
      
      
      DAB Divisions
    
                                                  
                              
            
      
      
      
      Contact DAB
    
                                                  
                                                    
            
      
      
      
      Filing an Appeal Online
                                            
            
            DAB E-File
    
                                                  
                              
            
      
      
      
      Medicare Operations Division (MOD) E-File
    
                                                  
                                                    
            
      
      
      
      Different Appeals at DAB
                                            
            
            Appeals to DAB Administrative Law Judges (ALJs)
                          
            
            Forms
    
                                                  
                              
            
      
      
      
      Procedures
    
                                                                
                                                    
            
      
      
      
      Appeals to Board
                          
            
            Practice Manual
    
                                                  
                              
            
      
      
      
      Guidelines
    
                                                  
                              
            
      
      
      
      Regulations
    
                                                  
                              
            
      
      
      
      National Coverage Determination Complaints
    
                                                                
                                                    
            
      
      
      
      Appeals to the Medicare Appeals Council (Council)
                          
            
            Forms
    
                                                  
                              
            
      
      
      
      Fully Integrated Duals Advantage (FIDA) Demonstration Project
    
                                                  
                                                    
            
      
      
      
      Alternative Dispute Resolution Services
                                            
            
            Sharing Neutrals
    
                                                  
                              
            
      
      
      
      ADR Training
    
                                                  
                              
            
      
      
      
      Other ADR Services
    
                                                  
                                                    
            
      
      
      
      DAB Decisions
                                            
            
            Board Decisions
    
                                                  
                              
            
      
      
      
      DAB Administrative Law Judge (ALJ) Decisions
    
                                                  
                              
            
      
      
      
      Medicare Appeals Council (Council) Decisions
    
                                    
                              
            
      
      
      
      Stakeholder Feedback
    
                                                  
                                                    
            
      
      
      
      Careers
                                            
            
            Open Career Opportunities
    
                                                  
                              
            
      
      
      
      Internships & ExternshipsText resize icon

                    




*In re* LCD Complaint: Rituximab (L33394), DAB CR6220 (2023)








  
  
    

  
      
Department of Health and Human Services 
    DEPARTMENTAL APPEALS BOARD
          Civil Remedies Division





*In re* LCD Complaint:
Rituximab (LCD No. L33394)
Docket No. C-22-235Decision No. CR6220January 19, 2023

        
              
    

      DECISION DISMISSING COMPLAINT

On January 5, 2022, the Civil Remedies Division (CRD) of the Departmental Appeals Board, United States Department of Health & Human Services (DHHS), received correspondence from Dr. Tamara H. W. Schwartz challenging a local coverage determination (LCD) for the use of Rituximab in treating chronic inflammatory demyelinating polyneuropathy (CIDP), on behalf of her patient, Sandra Cort.  On January 18, 2022, I issued an Acknowledgment of Receipt and Order to Aggrieved Party to Amend Unacceptable Complaint.

Sandra Cort, the Aggrieved Party (AP), filed an amended complaint on February 4, 2022.  The amended complaint incorrectly identified the LCD being challenged as L35026.  In response, an Order was issued on March 4, 2022, requesting a copy of the initial denial notice and clarification regarding the Medicare contractor using the LCD.  On March 16, 2022, the AP responded and provided National Government Services, Inc. (NGS) as the name of the Medicare contractor using the LCD.  An Order Finding Amended Complaint Acceptable, Order to File LCD Record, and Briefing Schedule was issued on March 30, 2022.

On April 1, 2022, NGS filed a Motion for Clarification Regarding Amended Complaint.  On April 4, 2022, I issued an order giving the AP a deadline of April 18, 2022 to respond  and giving NGS a deadline of May 2, 2022 to reply.  On April 18, 2022, Robert Squier, Jr., counsel for NGS, filed a Waiver of Reply and Motion to Correct Caption, moving to amend the case caption to reflect the LCD number being challenged as L33394.  On April 20, 2022, NGS’s motion was granted, and the case caption was amended to reflect the

**Page 2**

correct LCD number.  On April 27, 2022, NGS filed a Notice of Agreement to Stay Proceedings, requesting a stay until November.  The request was granted on May 3, 2022.

On November 1, 2022, NGS filed a document titled “Notice of Revised Local Coverage Determination and Article and Request for Dismissal Under 42 CFR § 426.420(e).”  In the notice, NGS stated that it had issued Local Coverage Determination (LCD) L39297 and the implementing Article A59101, which were filed with the notice as NGS Exhibit 4 and NGS Exhibit 5, respectively.1  NGS stated that, under LCD L39297, “ICD-10 code G61.81 (chronic inflammatory demyelinating polyneuritis or CIDP) has been added to the list of permitted and covered uses for Rituximab.”2  NGS asserted that “[c]laims by the Aggrieved Party for Rituximab to treat her CIDP will be covered and will not be denied outright under this new LCD.  However, such claims will remain subject to all other applicable Medicare rules and requirements.”  Based on the foregoing, NGS moved that I dismiss the Aggrieved Party’s complaint in accordance with 42 C.F.R. § 426.420(e).

Pursuant to my order dated November 9, 2022, the AP was directed to file a response to NGS’s filing, indicating the AP’s position on NGS’s request for dismissal.

In a response filed on November 15, 2022, the AP opposed dismissal of this case, and instead, requested a 120-day extension, stating that this time frame would allow for Medicare to either process or deny claims for the December infusions of Rituximab which the AP was scheduled to receive.

Pursuant to my Order dated November 23, 2022, the parties were advised that this case was stayed until February 21, 2023.  The AP was directed to submit a status report by February 21, 2023, which addressed the status of the most recent Rituximab claim(s).

On December 14, 2022, the AP filed a letter stating that she “received a claim summary from Medicare and the most recent service for Rituximab was processed and approved.  Based on this information, I agree with the dismissal of this case.”

**Page 3**

I construe the AP’s December 14, 2022 correspondence to be a withdrawal of the complaint.  Pursuant to 42 C.F.R. § 426.423(a), an aggrieved party may withdraw a complaint before an administrative law judge (ALJ) issues a decision regarding the LCD.

Further, under the regulations, “[i]f the ALJ receives a withdrawal notice regarding an LCD before the date the ALJ issued a decision regarding that LCD, the ALJ issues a decision dismissing the complaint under § 426.444 and informs the aggrieved party that he or she may not file another complaint to the same coverage determination for 6 months.”  42 C.F.R. § 426.423(c)(1); *see* 42 C.F.R. § 426.444(b)(7).

Because the AP has withdrawn the complaint prior to the issuance of a decision, I dismiss the complaint.  The AP may not file another complaint challenging the same LCD for six months.  42 C.F.R. § 426.423(c)(1).

Endnotes

1  The LCD which is the subject of the Aggrieved Party’s complaint is L33394.  However, the LCD referenced by NGS in its motion is “LCD L39297,” and NGS refers to this LCD as a “new LCD.”  It appears that NGS issued a new LCD to cover the off-label use of Rituximab and Rituximab Biosimilars.  NGS Ex. 4.  It is unclear whether LCD L33394 was actually revised.  However, it is unnecessary for me to address this further inasmuch as I find dismissal appropriate based on the Aggrieved Party’s withdrawal of her complaint.

2  Please note that “CIDP” is also known as “chronic inflammatory demyelinating polyneuropathy.”  *See* NGS Ex. 4 at 6.
  
          /s/
        Tannisha D. Bell

                      Administrative Law Judge Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility Statement
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​ Disclaimer Policy: Links with this icon () mean that you are leaving the HHS website. The Department of Health and Human Services (HHS) cannot guarantee the accuracy of a non-federal website.
                  Linking to a non-federal website does not mean that HHS or its employees endorse the sponsors, information, or products presented on the website. HHS links outside of itself to provide you with further information.
                  You will be bound by the destination website's privacy policy and/or terms of service when you follow the link.
                  HHS is not responsible for Section 508 compliance (accessibility) on private websites. For more information on HHS's web notification policies, see Website Disclaimers.
 Continue
                  Go back